Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

被引：15
|
作者：
Shang, X. [1 ]
Zhang, C. [1 ]
Zhao, G. [2 ]
Zhang, W. [3 ]
Liu, L. [3 ]
Duan, X. [1 ]
Yue, J. [1 ]
Ma, Z. [1 ]
Chen, C. [1 ]
Meng, B. [2 ]
Ren, X. [3 ]
Jiang, H. [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Minimally Invas Esophageal Surg, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1428 / S1429
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
    Zhang, Zhi
    Ye, Jinjun
    Li, Hui
    Gu, Dayong
    Du, Mingyu
    Ai, Dashan
    Chen, Wei
    Fang, Ying
    Xu, Xinyu
    Bai, Chenguang
    Zhao, Kuaile
    Zhou, Guoren
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial
    Wu, Wenjie
    Yao, Jie
    Zhang, Tong
    Zhang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)
    Yang, Yingnan
    Zhang, Jinfeng
    Meng, Hongxue
    Ling, Xiaodong
    Wang, Xiaoyuan
    Xin, Yanzhong
    Jiang, Hao
    Zhang, Luquan
    Fang, Chengyuan
    Liang, Hao
    Ma, Jianqun
    Zhu, Jinhong
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) : 1430 - 1440
  • [24] A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1)
    Xu, Peiran
    Su, Polan
    Wang, Weiwei
    He, Jia
    Zhao, Luo
    Zhou, Weixun
    Merritt, Robert
    Li, Li
    He, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Multi-omics analysis of tislelizumab plus nab-paclitaxel and cisplatin as neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A prospective single-arm phase II trial
    Xie, Z.
    Zhang, W.
    Chen, X.
    Wang, X.
    Liu, S.
    Yi, J.
    An, C.
    Lu, H.
    Yao, J.
    Zhu, H.
    Xie, T.
    Tang, L.
    He, X.
    Shi, Y.
    Gui, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S641 - S641
  • [26] Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial
    Lu, Zhihao
    Cao, Yanshuo
    Dai, Liang
    Dong, Fengxiao
    Shen, Lin
    CANCER RESEARCH, 2024, 84 (07)
  • [27] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Ding, Chengzhi
    Guo, Yijun
    Zhou, Yaning
    He, Yi
    Chen, Chunji
    Zhang, Ming
    Guo, Xufeng
    BMC CANCER, 2023, 23 (01)
  • [28] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Chengzhi Ding
    Yijun Guo
    Yaning zhou
    Yi He
    Chunji Chen
    Ming Zhang
    Xufeng Guo
    BMC Cancer, 23
  • [29] Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study
    Lin, Wenbao
    Huang, Yangyun
    Zhu, Lihuan
    Li, Wujin
    Zhao, Lilan
    Pan, Xiaojie
    Lin, Jinlan
    Guo, Tianxing
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (06) : 2758 - 2768
  • [30] A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
    Duan, Hongtao
    Wang, Zhaoyang
    Cao, Lili
    Zhu, Yifang
    Tong, Liping
    Yan, Xiaolong
    THORACIC CANCER, 2024, 15 (19) : 1471 - 1476
12345